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S U M M A R Y
Background: Previous treatment has been documented as a major risk factor for multidrug-resistant
tuberculosis (MDR-TB). However, risk factors for MDR-TB among previously treated patients in China are
unclear. This study aimed to ascertain the risk factors for MDR-TB in this particular population in China.
Methods: A case–control study was conducted from July through August 2011 in ﬁve cities of Zhejiang
Province. Cases were previously treated TB patients who had disease resistant to at least isoniazid and
rifampin, whereas controls were previously treated TB patients who had disease sensitive to isoniazid
and rifampin.
Results: Ninety-eight cases and 83 controls were identiﬁed. Multivariate analysis showed that a duration
of ﬁrst treatment of more than 8 months (odds ratio (OR) 2.18, 95% conﬁdence interval (CI) 1.05–4.52),
more than three prior episodes of anti-TB treatment (more than 2 months of continuous treatment as
one episode) (OR 5.57, 95% CI 2.38–13.00), adverse effects of anti-TB medication (OR 3.63, 95% CI 1.79–
7.36), and more than three TB foci in the lung (OR 2.17, 95% CI 1.08–4.37) were associated with MDR-TB
in previously treated TB patients. Low family income (p = 0.056) was marginally signiﬁcant in the
univariate analysis.
Conclusions: Particular clinical diagnostic results, such as more than three TB foci in the lung, non-
standard or irregular therapy, and adverse effects of anti-TB medication, were found to be associated
with MDR-TB in previously treated TB patients. High quality directly observed treatment should be
strengthened to ensure that the previously treated patients can receive standard and regular regimens.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The emergence of drug-resistant tuberculosis (TB), especially
multidrug-resistant tuberculosis (MDR-TB) and extensively
drug-resistant tuberculosis (XDR-TB), poses a substantial threat
to TB control programs worldwide.1 MDR-TB is deﬁned as TB
caused by strains of Mycobacterium tuberculosis that are resistant
to at least isoniazid and rifampin, while XDR-TB is deﬁned as
MDR-TB plus resistance to a ﬂuoroquinolone and at least one
second-line injectable agent (amikacin, kanamycin, or capreo-
mycin).2 MDR-TB requires prolonged therapy with a combina-
tion of second-line anti-TB drugs, many of which are less
effective, more toxic, and more expensive than ﬁrst-line drugs.3,4
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Health Organization (WHO) in patients who are treated under
strict observation.3
Nearly half a million cases of MDR-TB emerge every year as a
result of improper treatment of TB patients and transmission of
disease in congregate settings.2 In 2009, the WHO estimated that
China had the second largest number of MDR-TB patients in the
world,5 and approximately a quarter of the world’s MDR-TB
patients are in China.6 The national baseline survey of drug-
resistant TB undertaken in China in 2007–2008 indicated that the
MDR rate in TB patients was 8.3% and that an estimated 120 000
new MDR-TB patients emerged annually.7
In 2008, the WHO reported that the global weighted mean rate
of MDR was 2.9% among new patients and 15.3% among previously
treated patients.8 Many studies conducted in different countries
and territories have shown the same results, i.e., the MDR rate is
much higher in previously treated TB patients than in new TB
patients.9–11 In addition, previous research has found previous TB
treatment, gender, age, poor living conditions, the presence of ases. Published by Elsevier Ltd. All rights reserved.
250 previously treated MDR-TB patients
104 patients were hard to contact or 
unwilling to participate in the study
146 previously treated MDR-TB patients
48 patients did not have complete 
detailed medical records
98 cases were included in analysis
Figure 1. Flow chart of case selection.
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unemployment, poor medical management of the patient’s
treatment, lack of directly observed treatment, abandonment of
treatment, and limited or interrupted drug supplies to be
associated with drug-resistant TB or MDR-TB.12–16 A meta-analysis
including 16 studies by Zhao et al. found that poor quality Directly
Observed Treatment, Short course chemotherapy (DOTS), poor
treatment adherence, previous treatment, and poverty were risk
factors for MDR-TB in mainland China.17 However, risk factors for
MDR-TB among previously treated patients have not been well
documented in eastern China. In order to explore the risk factors
for MDR-TB more effectively, we thus selected previously treated
TB patients as our study population.
Zhejiang Province, a coastal province located in eastern
China, has an area of 104 141 square kilometers and had a
population of 56 137 000 in 2011. Wang et al. reported that
previously treated TB patients in Zhejiang Province were
more likely to have MDR-TB (OR 9.0, 95% CI 6.4–12.7) compared
to new TB patients.18 Funded by the Global Fund Tuberculosis
Control Project, drug resistance surveillance was conducted
in ﬁve cities of Zhejiang Province from 2010. The study was
conducted in these ﬁve cities to explore the risk factors
for multidrug resistance among previously treated patients
with TB.
2. Materials and methods
2.1. Study population and design
A case–control study was carried out from July through
August 2011 in ﬁve cities (Hangzhou, Huzhou, Shaoxing, Quzhou,
and Lishui) that conducted drug resistance surveillance in
Zhejiang Province. In Zhejiang, all sputum smear-positive
patients detected in a specialized TB hospital in the county
were referred to a municipal specialized TB hospital, where
further diagnosis was made by sputum culture. The sputum
specimens of sputum culture-positive patients were the sent to
the Tuberculosis Reference Laboratory (TRL) at the Zhejiang
Provincial Center for Disease Control and Prevention, where drug
susceptibility testing (DST) and bacterium identiﬁcation tests
were performed. After that, the diagnosis results were fed back to
the municipal specialized TB hospital to conﬁrm whether the
patients had MDR-TB or not. In this study, the medical records of
all TB patients in the municipal specialized TB hospital were
checked, after which the patients who met the inclusion criteria
were contacted consecutively for informed consent. The inclu-
sion criteria for the cases were as follows: (1) M. tuberculosis
detected in the patient’s bacterium identiﬁcation test; (2) strains
resistant to at least isoniazid and rifampin by DST, which was
routinely performed on isolates of M. tuberculosis by the
proportion method (minimum inhibitory concentration: isonia-
zid 0.2 mg/ml, rifampin 40 mg/ml, streptomycin 4 mg/ml, etham-
butol 2 mg/ml, kanamycin 30 mg/ml, oﬂoxacin 2 mg/ml); (3) a
history of treatment with anti-TB drugs for more than 1 month,19
i.e., treatment classiﬁcation in the medical records was ‘previ-
ously treated’, including relapses, treatment after failure,
treatment after default, and chronic patients;3 (4) patient was
registered between March 1, 2010 and August 31, 2011; (5)
willing to participate in the study; and (6) complete medical
records available.
The inclusion criteria for the controls were the same as those for
the cases, except that the strains were sensitive to both isoniazid
and rifampin by DST.
The exclusion criterion for cases and controls was: the patient
could not provide correct information, such as TB patients with
mental illness or alcohol abuse patients.2.2. Data collection
A structured questionnaire was used to collect information. A
pilot test was carried out to determine any inappropriate content
or logic errors in the questionnaire, and necessary modiﬁcations
were made. After obtaining informed consent, a face-to-face
interview was conducted among recruited patients to collect
information on demographic characteristics and risk factors,
including gender, age, ethnicity, occupation, education, social
and economic factors, work environment, history of previous
treatment, adverse effects of anti-TB medication, and knowledge of
TB. Other information such as height, weight, clinical diagnosis,
and DST results were obtained directly from the medical records.
Investigators were trained before interview to reduce the
investigation bias.
2.3. Statistical analysis
All data were double-entered into EpiData 3.1 (Denmark) and
discrepancies were checked against the raw data. The data analysis
was performed using SPSS 16.0 software (SPSS Inc., Chicago, IL,
USA). In the univariate analysis, the Chi-square test and Fisher’s
exact test, as well as the Student’s t-test (two-sided), were
performed to identify risk factors for MDR-TB, and a p-value less
than 0.05 was considered statistically signiﬁcant. In order to
control for confounding factors such as gender and age, a
multivariate analysis was performed by forward stepwise (likeli-
hood ratio) multiple logistic regression. In the forward stepwise
regression, independent variables with a p-value less than 0.10
were included in the logistic model, while variables with a p-value
more than 0.15 were removed. Multicollinearity among indepen-
dent variables was explored using collinearity diagnostics and was
expressed as the variance inﬂation factor (VIF), condition index,
and variance proportions. VIF and condition index 10 were
considered as obviously collinear. Variables included in the ﬁnal
model were chosen based on the univariate analysis (p < 0.10) as
well as biological plausibility. The odds ratio (OR) and 95%
conﬁdence interval (95% CI) were calculated to evaluate the
magnitude of association between risk factors and MDR-TB.
3. Results
3.1. Patients
A total of 250 previously treated patients were diagnosed with
MDR-TB in ﬁve cities of Zhejiang Province between March 2010
and August 2011. Of these, 104 patients were hard to contact or
unwilling to participate in the study and 48 patients did not have
complete detailed medical records. Therefore, the total number of
Table 2







Gender, n (%) 0.210a
Male 70 (71.4) 66 (79.5)
Female 28 (29.6) 17 (20.5)
Age, years, mean  SD 47.11  16.25 47.90  15.73 0.741b
Ethnicity, n (%) 1.000a
Han nationality 95 (96.9) 81 (97.6)
Minority 3 (3.1) 2 (2.4)
Permanent local residence, n (%) 0.871a
Yes 65 (66.3) 56 (67.5)
No 33 (33.7) 27 (32.5)
Education, n (%) 0.343a
Below elementary school 17 (17.3) 18 (21.7)
Elementary school 28 (28.6) 26 (31.3)
Middle school 29 (29.6) 27 (32.5)
Senior high school or technical
school
19 (19.4) 7 (8.4)
College, university, or above 5 (5.1) 5 (6.0)
Number of TB foci in the lung, n (%) 0.034a
>3 58 (59.2) 36 (43.4)
3 40 (40.8) 47 (56.6)
Total time of ﬁrst treatment, n (%) <0.001a
8 months 48 (49.0) 19 (22.9)
<8 months 50 (51.0) 64 (77.1)
Prior episodes of anti-TB
treatment, n (%)
<0.001a
3 times 43 (43.9) 10 (12.0)
<3 times 55 (56.1) 73 (88.0)
Adverse effects of anti-TB
medication, n (%)
<0.001a
Yes 66 (67.3) 32 (38.5)
No 32 (32.7) 51 (61.5)
Loss of appetite when ﬁrst infected
with M. tuberculosis, n (%)
0.080a
Yes 23 (23.5) 11 (13.3)
No 75 (76.5) 72 (86.7)
Area of bedroom 0.268a
18 m2 51 (52.0) 50 (60.2)
>18 m2 47 (48.0) 33 (39.8)
Exposed to dust at work, n (%) 0.775a
Yes 15 (15.3) 14 (16.9)
No 83 (84.7) 69 (83.1)
Who reminded you to take medicine
in ﬁrst treatment, n (%)
0.986a
Family members or doctors or
volunteers
66 (67.3) 56 (67.5)
Nobody 32 (32.7) 27 (32.5)
Total family income in a year, n (%) 0.056a
5000 yuan 21 (21.4) 9 (10.8)
>5000 yuan 77 (78.6) 74 (89.2)
Total time living as local 0.088a
S. Chen et al. / International Journal of Infectious Diseases 17 (2013) e1116–e1120e1118cases enrolled in the study was 98 (Figure 1); most of them (52,
53.1%) were from the city of Hangzhou. We also identiﬁed 83
controls in the ﬁve cities of Zhejiang Province, in accordance with
the inclusion criteria. There were no statistically signiﬁcant
differences between recruited patients and non-respondents in
gender (p = 0.324), age (p = 0.540), ethnicity (p = 0.303), or resi-
dence (p = 1.000) (Table 1).
The mean age of cases was 47.11  16.25 years; 70 (71.4%) were
male. Ninety-ﬁve cases (96.9%) were of Han nationality and only three
were of minority ethnicity. About two-thirds (66.3%) were permanent
local residents while one-third (33.7%) were not. The education levels
of the cases were as follows: 57 (58.2%) had ﬁnished elementary
school or graduated from middle school and 17 (17.3%) had never
been to school or did not ﬁnish elementary school.
In the control group, the mean age was 47.90  15.73 years; 66
(79.5%) were male. As in the case group, the majority of control
patients (81, 97.6%) were of Han nationality. There were more
permanent local residents (56, 67.5%) than non-local residents (27,
32.5%). The number of patients who had ﬁnished elementary or
middle school was 53 (63.9%), and 18 (21.7%) had never been to
school or did not ﬁnish elementary school.
No signiﬁcant difference was observed between cases and
controls with regard to gender (p = 0.210), age (p = 0.741),
ethnicity (p = 1.000), residence (p = 0.871), or level of education
(p = 0.343) (Table 2).
Five XDR-TB patients were found among the 98 cases. All TB
patients were tested for HIV and no case or control patient was
HIV-positive.
3.2. Risk factors associated with MDR-TB among previously treated
patients—univariate analysis
In the univariate analysis, four factors were associated with
MDR-TB: a duration of ﬁrst treatment of more than 8 months
(p < 0.001), more than three prior episodes of anti-TB treatment
(more than 2 months of continuous treatment as one episode)
(p < 0.001), adverse effects of anti-TB medication during
treatment (p < 0.001), and more than three TB foci in the lung
(p = 0.034). A bedroom area of 18 m2 (p = 0.268), being exposed
to dust at work (p = 0.775), loss of appetite when ﬁrst infected
with M. tuberculosis (p = 0.080), being reminded to take medicine
on time by someone during the ﬁrst treatment (p = 0.986), family
income (p = 0.056), living locally for less than 30 years
(p = 0.088), knowledge of TB (p = 0.914), and cavities in the lung
(p = 0.194) were not signiﬁcantly associated with MDR-TB
(Table 2).Table 1
Characteristics of recruited and non-respondent previously treated MDR-TB








Gender, n (%) 0.324a
Male 70 (71.4) 117 (77.0)
Female 28 (29.6) 35 (23.0)
Age, years, mean  SD 47.11  16.25 48.49  17.94 0.540b
Ethnicity, n (%) 0.303a
Han nationality 95 (96.9) 151 (99.3)




Yes 65 (66.3) 102 (67.1)
No 33 (33.7) 50 (32.9)
MDR-TB, multidrug-resistant tuberculosis; SD, standard deviation.
a Calculated by Chi-square or Fisher’s exact test (two-sided).
b Calculated by Student’s t-test (two-sided).
resident, n (%)
30 years 49 (50.0) 31 (37.3)
>30 years 49 (50.0) 52 (62.7)
Knowledge of TB, n (%) 0.914a
Score 0–5 35 (35.7) 29 (34.9)
Score 6–7 63 (64.3) 54 (65.1)
Cavities in the lung, n (%) 0.194a
Yes 46 (46.9) 31 (37.3)
No or missing datac 52 (53.1) 52 (62.7)
MDR-TB, multidrug-resistant tuberculosis; SD, standard deviation.
a Calculated by Chi-square or Fisher’s exact test (two-sided).
b Calculated by Student’s t-test (two-sided).
c Eight cases and four controls missed data in ‘cavities in the lung’.3.3. Risk factors associated with MDR-TB among previously treated
patients—multivariate analysis
The four statistically signiﬁcant factors, as well as three
variables with a p-value less than 0.10 in Table 2, were selected
for the multivariate logistic model. Gender and age were also
included in the model. Factors that remained signiﬁcant in the
Table 3










Total time of ﬁrst treatment, n (%) 0.036
8 months 48 (49.0) 19 (22.9) 3.23 (1.69–6.18) 2.18 (1.05–4.52)
<8 months 50 (51.0) 64 (77.1) 1 1
Prior episodes of anti-TB treatment, n (%) <0.001
3 times 43 (43.9) 10 (12.0) 5.71 (2.64–12.35) 5.57 (2.38–13.00)
<3 times 55 (56.1) 73 (88.0) 1 1
Adverse effects of anti-TB medication, n (%) <0.001
Yes 66 (67.3) 32 (38.6) 3.29 (1.78–6.06) 3.63 (1.79–7.36)
No 32 (32.7) 51 (61.4) 1 1
Number of TB foci in the lung, n (%) 0.029
>3 58 (59.2) 36 (43.4) 1.89 (1.05–3.42) 2.17 (1.08–4.37)
3 40 (40.8) 47 (56.6) 1 1
Gender, n (%) 0.468
Male 70 (71.4) 66 (79.5) 0.64 (0.32–1.28) 0.73 (0.31–1.71)
Female 28 (29.6) 17 (20.5) 1 1
Age, y, n (%)
>55 35 (35.7) 31 (37.4) 0.85 (0.32–2.28) 0.90 (0.27–2.98) 0.869
41–55 21 (21.4) 24 (28.9) 0.66 (0.23–1.86) 0.81 (0.23–2.83) 0.736
26–40 30 (30.6) 19 (22.9) 1.18 (0.42–3.34) 1.22 (0.37–4.04) 0.745
25 12 (12.2) 9 (10.8) 1 1
MDR-TB, multidrug-resistant tuberculosis; OR, odds ratio; CI, conﬁdence interval.
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ﬁrst treatment of more than 8 months (p = 0.031), more than three
prior episodes of anti-TB treatment (p < 0.001), adverse effects of
anti-TB medication (p < 0.001), and more than three TB foci in the
lung (p = 0.036). Since gender and age were common confounders,
they were kept in the model compulsively. Factors that remained
signiﬁcant in the ﬁnal model were: a duration of ﬁrst treatment of
more than 8 months (OR 2.18, 95% CI 1.05–4.52), more than three
prior episodes of anti-TB treatment (OR 5.57, 95% CI 2.38–13.00),
adverse effects of anti-TB medication (OR 3.63, 95% CI 1.79–7.36),
and more than three TB foci in the lung (OR 2.17, 95% CI 1.08–4.37)
(Table 3). In the collinearity diagnostics, VIFmax was 1.69 and the
maximal condition index was 34.16. The corresponding variance
proportions of age and ‘total time living as a local resident’ were
0.80 and 0.69, respectively, when the condition index was 13.44.
The results were not affected seriously by the mild collinearity.
4. Discussion
In this study, which took place in an eastern province of China,
we identiﬁed several risk factors for MDR-TB. We found that
previously treated TB patients who had more than three TB foci in
the lung constituted a high-risk population for MDR-TB. TB foci and
cavities are different clinical manifestations in TB patients, and
more cavities or TB foci predict a more severe illness, which is a
potential risk factor for the development of acquired drug
resistance.20 Thus more attention should be paid to TB patients
with this particular clinical manifestation. However, the associa-
tion between cavities and MDR-TB was not signiﬁcant in this study,
which is in contrast to many other studies. A survey in young
Korean soldiers showed that the presence of a cavity on the
patient’s chest computed tomography scan was associated with
MDR-TB.12 Another study in India indicted that a higher number of
cavities on chest radiographs was an independent predictor of
MDR-TB.20 Cavities were not associated with MDR-TB in this study,
maybe due to missing data or an insufﬁcient number of controls.
The study also indicated that a duration of ﬁrst treatment of
more than 8 months and having had more than three prior
episodes of anti-TB treatment were associated with MDR-TB. In
China, TB patients generally receive 6 or 8 months of treatment the
ﬁrst time. More than 8 months of treatment the ﬁrst time or more
than three prior episodes of anti-TB treatment increase the risk ofreceiving non-standard regimens or interrupted treatment.13 A
sub-minimum inhibitory concentration effect might occur when
TB patients receive non-standard regimens, i.e., the sensitive
strains would be killed and mutant MDR strains would take the
place of the sensitive ones, resulting in the emergence of MDR-
TB.21 A study conducted in Uganda showed similar results – that
multiple previous episodes and therapies of TB were associated
with MDR-TB.22 Another study also indicated that longer non-
standard regimens resulted in more MDR-TB patients in Jiangxi,
China.23 Hence, it is important to ensure TB patients receive
standard regimens, that interrupted treatment is avoided, and that
poor adherence to treatment is reduced. Patient care and education
are also necessary to ensure that TB patients receive standard and
regular therapy. According to an analysis in Zhejiang, the general
level of qualiﬁcation of staff in county-level medical institutions
for TB control and treatment is relatively low compared with that
of staff at the municipal level, and this inﬂuences the standard
treatment of TB patients.24 More guidance and training should be
given to staff in order to improve the effect of therapy.
Side effects of anti-TB medicine are an inherent risk for patients
commencing any type of anti-TB therapy, especially those with
drug-resistant disease.25 This study found that adverse effects of
anti-TB medication were associated with MDR-TB among previ-
ously treated TB patients. The reason for this might be that MDR-TB
patients had previously received second-line treatment for MDR or
they had received many more treatments than other patients.
DOTS is necessary to ensure that TB patients receive standard
treatment, and the management of second-line drugs should be
strengthened. Patients with TB in general hospitals and clinics
should also be monitored and supervised properly, because the
DOTS strategy in China has been implemented only in designated
TB dispensaries.26
Low family income (p = 0.056) just failed to reach statistical
signiﬁcance in the univariate analysis, but it may become another
risk factor with a sufﬁcient number of controls. Poverty, living on
ﬁnancial assistance, and lack of health insurance have been
associated with MDR-TB in previous studies.17,27,28 Patients with a
low family income may have more limited access to medical
treatment and healthcare services, and their crowded and poor
living conditions may facilitate the spread of infectious disease.29
Hence, these lower socioeconomic groups should be the highest
priority for MDR-TB prevention efforts.28
S. Chen et al. / International Journal of Infectious Diseases 17 (2013) e1116–e1120e1120There are several limitations to our study. First, the number of
patients in the control group was less than the number in the case
group. The reason for this is that many previously treated MDR-TB
patients have disease that is resistant to either isoniazid or
rifampin, and the number of patients who have disease sensitive to
both isoniazid and rifampin is small, making it difﬁcult to identify
enough patients to meet the inclusion criteria of the control group.
Second, we could not exclude cases who were initially infected
with an MDR strain in a previous episode. For these patients, the
initial infection rather than other factors was the true reason for
MDR-TB. Third, many eligible MDR-TB patients were not included
in the analysis, because some of them were hard to contact or
unwilling to participate in the study and others did not have
complete detailed medical records. Although there were no
signiﬁcant differences in demographic characteristics between
recruited MDR-TB patients and those who were not, the recruited
cases may still not represent all cases in the ﬁve cities. As a result
the conclusions of the study are limited when they are generalized.
In summary, our study identiﬁed some risk factors associated
with MDR-TB. Based on our ﬁndings, we suggest that in order to
control MDR-TB, we should pay more attention to previously
treated TB patients with speciﬁc clinical manifestations such as
more than three TB foci in the lung. DOTS should be strengthened
to ensure that previously treated patients can receive standard and
regular regimens.
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